Urgent Copper Stock With Strong Catalysts
Quebec discovery. Strong grades. Roads and hydro in place. Funding secured for a busy drill calendar. Each assay can build scale and tighten the window for early entries as EVs and data centers pull harder on copper. Do not wait.
FDA's Prasad Cites Alleged Child COVID Shot Deaths in Push for Stricter Rules
FDA's new vaccine strategy tightens approval rules after internal findings linked COVID-19 shots to several child deaths.
Analyst Sees Strong Medtronic Momentum Through 2026 With Buy Rating Intact
BofA expects Medtronic to post over 5% second-quarter revenue growth and maintain strong momentum through 2026, driven by robust procedure trends.
Nvidia's Plan to Dominate the World of Robotics ... - Ad
Robots just had a coming-out party in Las Vegas. From household helpers to rescue bots, they're now essential-not just novelties. Forbes says it's a $24T opportunity. And Nvidia's CEO says one $7 stock is key to building the world's first trillion-dollar robot.
Why Is Scholar Rock Holding Stock Climbing Today?
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
New FDA-approved glasses can slow nearsightedness in kids
WASHINGTON (AP) — For many children, the experience of getting their first pair of glasses is an inevitable milestone, the first in a lifetime of visits to the eye doctor.
First Drug to Show Breakthrough Myocarditis Data. Analysts See Potential 7-10x Upside. - Ad
This biotech just delivered a medical first in myocarditis and has a Phase 3 trial fully funded into 2027. Wall Street targets imply massive revaluation ahead.
Some Social Security Recipients Get Double Payments In December And January
Social Security payments in Dec 2025 will be paid on Jan 30 & Dec 31. Feb's check will also come early. Retirees will receive COLA raise in Dec.
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy
Novo Nordisk files for FDA review of its higher-dose Wegovy after 72-week data show stronger weight loss than the current 2.4 mg option.
Why Are Wall Street Insiders Moving Their Money to This One Asset? - Ad
Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.
Trump EPA moves to abandon rule that sets tough standards for deadly soot pollution
WASHINGTON (AP) — The Trump administration is seeking to abandon a rule that sets tough standards for deadly , arguing that the Biden administration did not have authority to set the tighter standard on pollution from tailpipes, smokestacks and other industrial sources.
Small Caps, Pharma Surge As AI Rotation Broadens, Nvidia Tumbles: What's Moving Markets Tuesday?
Wall Street's sector rotation entered full throttle Tuesday, with investors pouring into previously overlooked corners of the market amid an AI-driven shift that now favors undervalued small caps and defensive names such as health care.
Bitcoin's Pullback Could Be Your Gain - Ad
More than 70 cryptos have recently outperformed Bitcoin and it's not the first time. During crypto's last bull market the top 100 coins NOT named Bitcoin went up by 174%. Now the signs show that it's happening again. This could be a chance to strike gold in some far corners of the crypto market.
AP Lifestyles Digest for week of Nov. 24
Here is the AP Lifestyles Digest for the week of Nov. 17. Note AP's Holiday Gift Guide Digest moved Nov. 12 and is included at the end.
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows
AstraZeneca boosts its Harbour BioMed collaboration and invests $2 billion to expand biologics manufacturing and clinical development capacity in Maryland.
Nevada's Mining Renaissance Is Accelerating - And This Early Opportunity Is Well Positioned - Ad
Nevada's Walker Lane belt has produced 50M+ ounces of gold since the 1800s, and it's waking up again. One of the neighborhood's latest successes just secured over $6M in U.S. support and is up more than 300% YTD. Now a new early-stage explorer has moved in next door.
Elon Musk-Led Neuralink's First Patient Details Life Post Receiving BCI Chip — Eyes Second Implant: 'It Gave Me Hope'
The first recipient of Elon Musk-led Neuralink's BCI implant shares his experiences and how it changed his life, eyeing a second implant.
Babies who drank ByHeart formula got sick months before botulism outbreak, parents say
As health officials investigate more than linked to ByHeart baby formula since August, parents who say their children were sickened with the same illness months before the current outbreak are demanding answers, too.
Urgent Copper Stock With Strong Catalysts - Ad
Quebec discovery. Strong grades. Roads and hydro in place. Funding secured for a busy drill calendar. Each assay can build scale and tighten the window for early entries as EVs and data centers pull harder on copper. Do not wait.
'Rental Family' spotlights real-life Japanese businesses that offer fill-in relatives, friends
TOKYO (AP) — Ryuichi Ichinokawa's life could be right out of the movie “Rental Family” as the founder nearly two decades ago of the Heart Project business in Japan, which he bills as a surrogate attendance service complete with furnishing of extras and family members.
Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'
Short seller challenges Praxis' Phase 3 ulixacaltamide data, alleging major flaws that could undermine FDA approval and the company's valuation.
The Next 'Ozempic Moment' Could Be in Heart Disease - Ad
Just as Ozempic rewrote the obesity playbook, this breakthrough data could transform how we treat inflammatory heart disease. Fully funded. Multiple catalysts. $280B market opportunity.
LOCALIZE IT: At least 30 babies in 15 states sickened by growing infant botulism outbreak
EDITORS/NEWS DIRECTORS:
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Copper Is Tight, Silver Is Rising - And This Early Nevada Play Hits the Timing Perfectly - Ad
AI, electrification, battery storage, and data centers are pushing copper and silver demand sharply higher, even as supply stays tight. This region in Nevada offers rare multi-metal potential, and a new company has secured land in a district the surging district. It's one of the cleanest timing setups in the sector right now.
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder
Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.
MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
NEW YORK (AP) — The MacArthur Foundation is awarding $100 million to a private pandemic prevention network across Africa, offering critical support to infectious disease surveillance at a time when governments are reducing global health spending.
Retire Comfortably with These New Monthly Income ETFs? - Ad
Retirement should be freedom, not stress. Yet outdated advice and tiny returns leave many trapped. Kelly G. broke free with a revolutionary income strategy once reserved for the wealthy - hitting her "Freedom Number" faster than she dreamed. You might already have enough too.
Novo Nordisk Leans Into Affordability Amid Rising Competition
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.
Novo chops Wegovy prices, but doctors still see affordability challenges for patients
Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain challenging for patients without insurance.
New Number One Copper Start Alert - Ad
EVs and AI devour copper. Supply cannot keep up. A Quebec discovery with high grade, infrastructure, and cheap power is funded to drill through the year. Catalysts are lining up. Institutions are circling. Move now while it is still early.
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.
Nvidia's Plan to Dominate the World of Robotics ... - Ad
Robots just had a coming-out party in Las Vegas. From household helpers to rescue bots, they're now essential-not just novelties. Forbes says it's a $24T opportunity. And Nvidia's CEO says one $7 stock is key to building the world's first trillion-dollar robot.
Workers take on side jobs to combat stagnant salaries and insecurity about employment
NEW YORK (AP) — As workers face , inflation and , some have decided to branch out from their traditional careers. They're taking on side jobs to bring in additional income and provide a backup plan should they , or adding second, third and sometimes fourth jobs — what some call “polyworking” — to the mix.
Federal workers question whether the longest government shutdown was worth their sacrifice
WASHINGTON (AP) — Jessica Sweet spent cutting back. To make ends meet, the Social Security claims specialist drank only one coffee a day, skipped meals, cut down on groceries and deferred paying some household bills. She racked up spending on her credit card buying gas to get to work.
First Drug to Show Breakthrough Myocarditis Data. Analysts See Potential 7-10x Upside. - Ad
This biotech just delivered a medical first in myocarditis and has a Phase 3 trial fully funded into 2027. Wall Street targets imply massive revaluation ahead.
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
More than 80 nonprofits receive $250M for global women's health from Melinda French Gates
More than 80 organizations that provide health care for women all over the world received grants Wednesday totaling after a year-long application process.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.